8/2/2019 as BAH II

1/13

Uji Bioaktivitas

Bersifat in vitro

Memberikan nilai manfaat pada ekstrak/senyawa hasil isolasi

Tahapan awal

8/2/2019 as BAH II

2/13

8/2/2019 as BAH II

3/13

Persyaratan utama skrining uji bioaktifitasprimer adalah:

(1) Hasil dari bioassay harus dapat memprediksi beberapa jenis

potensi terapi, baik secara langsung atau dengan analogimenggunakan obat klinik efekif yang juga juga telah di sriningmengunakan metode yang sama

(2) Potensi kemanfaatan aktifitas farmakologi tidak harusterdeteksi bahkan jika aktifitas tersebut tidak terduga ataupun

unik(3)The probable nature of the activity should be indicated so that

subsequent research can be organized intelligently.

(4) The primary bioassay screening test should be tolerant of themany impurities present in a crude extract and yet it should be

sensitive enough to reveal presence the potentially interestingsubstances present in low concentrations (levels of about0.0001% of an active compound in an extract, based on thedried weight of the extracted organism, should be detectable).

8/2/2019 as BAH II

4/13

(5) The bioassay procedure should be unbiased and itshould allow for the coding of all samples, including bothknown reference materials (standards) and unknown

test samples.

(6) The results obtained should be reproducible.

(7) The screen should allow the use of both crude materialsand pure isolates so that theprocedure can be used todirect the extraction, isolation and purification work of the

natural product chemist.

8/2/2019 as BAH II

5/13

(8) Completion of a single bioassay screen should not require morethan 1.02.0 g of the crude dry natural material (plant or animalextract).

(9) The primary bioassay screen should have a high throughput, even if

the informationcontent is low, with the results becoming availablequickly.

(10) The procedure should not require expensive equipment or asophisticated laboratory environment so that the primary levelscreening experiment can be conducted synchronously with thefractionation process.

(11) The procedure should be compatible with the use of dimethylsulfoxide (DMSO) since DMSO is commonly employed to solubilizeextracts or pre polar compounds for screening.

8/2/2019 as BAH II

6/13

(12) The procedure should be simple enough to be taught easily tolaboratory technicians so that highly trained and qualifiedresearchers are not required for the routine operation of thebioassay program.

(13) The test animals (if required for the bioassay) should be easilyobtainable, easily handled, easily bred and resistant to infections.

(14) Finally the bioassay should be economical to conduct overextended time periods.

8/2/2019 as BAH II

7/13

Choosing the Bioassay

Definitions:

In vitro: In an artificial environment, as in a testtube or culture media

In vivo: In the living body, referring to testsconductedin living animals

Ex vivo: Usually refers to doing the test on atissue taken from a living organism.

8/2/2019 as BAH II

8/13

Choosing the Bioassay (cont.)

In vitro testing

Has advantages in terms of speed and requiresrelatively small amounts of compound

Speed may be increased to the point where it ispossible to analyze several hundred compounds ina single day (high throughput screening)

Results may not translate to living animals

8/2/2019 as BAH II

9/13

Choosing the Bioassay (cont.)

In vivo tests

More expensive

May cause suffering to animals

Results may be clouded by interferencewith other biological systems

8/2/2019 as BAH II

10/13

8/2/2019 as BAH II

11/13

Bench-Top and primary bioassayscreening

Uji toksisitas

Uji anti mikroba

Uji antiviral dan anticancer Uji anti mikotik

Uji Genotoksisitas

Assay for control of tropical diseases Assay for agrochemical

Uji hepatotoksik

8/2/2019 as BAH II

12/13

Contd

Uji antidiabetes

Uji aktifitas diuretik

Uji aktifitas anthelmintik Uji antifertilitas

Uji invitro untuk platelet agregation

Uji anti inflamasi Uji Immunomodulating

Uji antikonvulsi/ antiepileptik

8/2/2019 as BAH II

13/13

Contd

Uji analgesik

Uji antiulcer/ gastroprotective

Radiolabelling Bioassay Uji anti emetik

Attur-rahman